Newsroom

Scientists at the NIH are pioneering better Covid-19 diagnostic methods using artificial intelligence and stacks of digital lung and heart images through a new project the agency announced Wednesday. Read more at Bloomberg Law.

The National Institutes of Health has launched an ambitious effort to use artificial intelligence, computation, and medical imaging to enable early disease detection, inform successful treatment strategies, and predict individual disease outcomes of COVID-19.

After scrutinizing several dozen submissions to its national, “Shark Tank”-esque pitch competition for new COVID-19 diagnostics technologies, the National Institutes of Health has selected its first seven projects that will move on to a new phase of manufacturing and scale-up—and has unlocked nearly a quarter of a billion dollars for the effort. Read more at Fierce Biotech
.

Researchers have reported a new form of electronics known as 'drawn-on-skin electronics,' allowing multifunctional sensors and circuits to be drawn on the skin with an ink pen.

Building on early-stage funding by NIBIB to develop an implantable artificial kidney, researchers at the University of California San Francisco were selected for a substantial prize in the HHS KidneyX Challenge.

The National Institutes of Health awarded $248.7 million to seven companies to accelerate the development of new coronavirus diagnostic technologies as the country grapples with rising case numbers and testing shortages. The federal research agency expects some of the companies to potentially be able to perform hundreds of thousands of tests come September. Read more at Forbes.

he National Institutes of Health selected Ginkgo Bioworks, Mammoth Biosciences, Quidel, and four other companies to receive nearly $250 million to develop new Covid-19 diagnostic tests through its Rapid Acceleration of Diagnostics program, the agency announced Friday. Read more at STAT.

On Friday, the NIH announced the first seven winners of a competition to produce next-generation coronavirus tests to help battle the spread of COVID-19. Together, they will receive $248.7 million to further develop their tests and hopefully make them available by the fall. Read more at NPR.

NIH is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus). NIH’s RADx initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests.